Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725007 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
A Phase 1 study of Juvenile Idiopathic Arthritis (JIA), sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT03725007: Active Phase 1 study of Juvenile Idiopathic Arthritis (JIA), sponsored by AbbVie.
NCT03725007 is a Phase 1 study of Juvenile Idiopathic Arthritis (JIA) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03725007, a Phase 1 study of Juvenile Idiopathic Arthritis (JIA), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability.
Primary Outcome
Adverse Event is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product.
Conditions Studied
Interventions
- DRUG Upadacitinib
Study Locations (20)
Other
- Helios Klinikum Berlin-Buch /ID# 206859 - Berlin
- Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 206571 - Hamburg
- Semmelweis Egyetem /ID# 208970 - Budapest
Pennsylvania
- Children's Hospital of Philadelphia /ID# 209617 - Philadelphia
- Children's Hospital of Pittsburgh of UPMC /ID# 202994 - Pittsburgh
North Rhine-Westphalia
- Asklepios Klinik Sankt Augustin /ID# 203264 - Sankt Augustin
- St. Josef-Stift Sendenhorst /ID# 244740 - Sendenhorst
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago /ID# 211162 - Chicago
Kentucky
- Duplicate_University of Louisville /ID# 202896 - Louisville
Massachusetts
- Boston Children's Hospital /ID# 202993 - Boston
Ohio
- Cincinnati Childrens Hospital Medical Center /ID# 209697 - Cincinnati
Oregon
- Randall Children's Hospital /ID# 213609 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What the registry record for NCT03725007 still lists
NCT03725007 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).
The record links to 1 condition, with Juvenile Idiopathic Arthritis (JIA) appearing as the primary indexed condition, and to 1 intervention - of which Upadacitinib is the first listed.
NCT03725007 names 20 study sites across 16 states, led by Other, Pennsylvania, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT03725007 about?
NCT03725007 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis". This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participa...
What is the current status of trial NCT03725007?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2019-06-24. Estimated completion is 2027-05.
What conditions does trial NCT03725007 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis (JIA).
What interventions are being tested in trial NCT03725007?
The interventions under investigation include: Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT03725007?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03725007 being conducted?
This trial has 20 study locations across Illinois, Kentucky, Massachusetts, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis (JIA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03725007's enrollment target sits among peer trials
124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI